ArticleIntestinal Failure (New York, N.Y.)
Conversion from SMOFlipid® to Omegaven® as a salvage therapy for intestinal failure associated liver disease.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neonatal growth with fish oil or mixed oil lipid emulsions in intestinal failure associated liver disease.Intestinal Failure (New York, N.Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intestinal failure associated liver disease (IFALD) is a common complication of intestinal failure with limited treatment options. While Omegaven® can be used as a salvage therapy for IFALD in patients receiving intralipid®, its efficacy in IFALD associated with SMOFlipid® remains unclear. This study aims to assess Omegaven® as a salvage therapy in this setting. Methods: Retrospective study of children with intestinal failure who developed advanced IFALD (conjugated bilirubin over 50 µmol/L for at least 2 weeks) while receiving SMOFlipid® and converted to Omegaven® (1.0 g/kg/d). Patients were treated with Omegaven® for at least 7 weeks. The primary outcome was conjugated bilirubin (CB) < 34 μmol/l after Omegaven® Initiation Results: Out of 219 patients receiving SMOFlipid® between 2013 and 2024, 13 developed advanced IFALD and were converted to Omegaven®. Two patients did not meet inclusion criteria. All 11 remaining patients had a high parenteral nutrition dependency index (PNDI) at baseline. Following conversion to Omegaven®, 7 (63.6 %) patients achieved CB bellow 34 µmol/L, in a mean time of 12.5 weeks (SD 6.63). Non-responders had a higher incidence of gastrointestinal bleeding secondary to portal hypertension (75 % vs 0 %, p = 0.02), INR (1.8 vs 1.1, p = 0.03), and need for continuous glucose infusion (75 % vs 0 %, p = 0.02). Out of the 4 non-responders, one patient died of liver failure, 2 underwent multivisceral transplantation, and one remains listed for liver-intestine transplantation. Conclusions: Conversion to Omegaven® from SMOFlipid® reversed advanced IFALD in 63.6 % of patients. Response is less likely in children with synthetic liver dysfunction and clinically significant portal hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.